HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
spiraprilat
Also Known As:
spiraprilate; 1,4-dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-, (8S- (7(R*(R*)),8R*))-
Networked:
5
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Peptides: 82426
Oligopeptides: 519
Dipeptides: 945
Enalapril: 3647
spiraprilat: 5
Related Diseases
1.
Heart Failure
08/01/1997 - "
Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure.
"
08/01/1997 - "
The aim of this study was to investigate the relations between the plasma concentrations of spiraprilat (the active metabolite of the angiotensin-converting enzyme inhibitor spirapril) and its effects on plasma converting enzyme activity (PCEA), pulmonary capillary wedge pressure (PCWP), and brachial blood flow (BBF), after a single oral administration of 6 mg of spirapril in eight patients with severe congestive heart failure (CHF).
"
2.
Tachycardia (Tachyarrhythmias)
01/01/1990 - "
We conclude that: a), in conscious dogs under normal sodium diet, spiraprilat reduces TPR and MAP through peripheral vasodilating properties; b), spiraprilat-induced tachycardia is mainly related to parasympathetic tone withdrawal, possibly in relation with high and low pressure baroreceptors deactivation; and c), sodium depletion considerably potentiates spiraprilat cardiac and hemodynamic effects.
"
01/01/1990 - "
Spiraprilat-induced tachycardia was not modified by propranolol pre-treatment but was abolished by previous administration of the propranolol-N-methylatropine combination.
"
3.
Liver Diseases (Liver Disease)
01/01/1993 - "
In contrast, the bioavailability of spiraprilat, the metabolite responsible for the pharmacological action of spirapril, was significantly reduced in patients (AUC 820 micrograms.h.l-1, 923 micrograms.h.l-1 and 1300 micrograms.h.l-1 in patients with cirrhosis, patients with non-cirrhotic liver disease and in healthy subjects, respectively.
"
4.
Chronic Kidney Failure (Chronic Renal Failure)
01/01/1994 - "
Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure.
"
5.
Hypertension (High Blood Pressure)
05/01/1995 - "
Spirapril is a non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor prodrug which is converted to the active metabolite spiraprilat following oral administration, and which has been evaluated primarily for the treatment of hypertension.
"
Related Drugs and Biologics
1.
spirapril
2.
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
3.
Enzymes
4.
Sodium
5.
Propranolol (Inderal)
6.
Prodrugs
7.
Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
8.
methylatropine
Related Therapies and Procedures
1.
Oral Administration